Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapanisertib + Exemestane/Fulvestrant in ER+/HER2- Breast Cancer
NCT02049957Phase 2Completed
- Sponsor
- Calithera Biosciences
- Start
- Feb 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of sapanisertib in breast cancer (9 arms), sponsored by Calithera Biosciences. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events up to 52 months and Clinical Benefit Rate at 16 Weeks. Started Feb 2014; status: completed.
02
Drugs
sapanisertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02049957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049957.